Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.
Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results